As genetic testing spreads, revolutionizing how doctors recognize and treat illness, this deeply reported story finds the insurance industry in a muddle. A genetic test one insurer calls “actionable,” another considers “unnecessary.” Some will pay to test sick patients, but not to find out who’s at risk of a disease. Barrett Rollins, HMS professor of medicine and chief scientific officer at Dana-Farber Cancer Institute, and Allison Cirino, genetic counselor at Brigham and Women’s Hospital, are quoted.
